Zhejiang Starry Pharm Co Ltd Cash Flow Conversion Efficiency
Zhejiang Starry Pharm Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥9.76 Million ≈ $1.43 Million USD) by net assets (CN¥2.61 Billion ≈ $381.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zhejiang Starry Pharm Co Ltd (2011–2025)
Cash flow conversion efficiency of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. This chart illustrates how Zhejiang Starry Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 603520 stock price for real-time trading data and today's change.
Zhejiang Starry Pharm Co Ltd Cash Flow Conversion Ratio Explained
Zhejiang Starry Pharm Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zhejiang Starry Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their cash flow conversion efficiency. Also see Zhejiang Starry Pharm Co Ltd (603520) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
0.228x |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
0.021x |
|
HCM II Acquisition Corp. Unit
NASDAQ:HONDU
|
-0.002x |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
-0.033x |
|
Inox Green Energy Services Limited
NSE:INOXGREEN
|
0.015x |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
0.009x |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
0.034x |
|
Assure Tech Hangzhou Co Ltd
SHG:688075
|
0.000x |
Annual Cash Flow Conversion Efficiency for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. Review Zhejiang Starry Pharm Co Ltd (603520) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.56 Billion ≈ $375.23 Million |
CN¥3.67 Million ≈ $536.56K |
0.001x | -98.05% |
| 2024-12-31 | CN¥2.63 Billion ≈ $385.50 Million |
CN¥193.50 Million ≈ $28.32 Million |
0.073x | +180.09% |
| 2023-12-31 | CN¥1.76 Billion ≈ $257.38 Million |
CN¥46.13 Million ≈ $6.75 Million |
0.026x | +159.27% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.18 Million |
CN¥-78.37 Million ≈ $-11.47 Million |
-0.044x | -119.26% |
| 2021-12-31 | CN¥2.21 Billion ≈ $324.06 Million |
CN¥508.84 Million ≈ $74.46 Million |
0.230x | +145.57% |
| 2020-12-31 | CN¥1.86 Billion ≈ $272.87 Million |
CN¥174.48 Million ≈ $25.53 Million |
0.094x | -60.99% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.53 Million |
CN¥246.77 Million ≈ $36.11 Million |
0.240x | +15.41% |
| 2018-12-31 | CN¥922.96 Million ≈ $135.06 Million |
CN¥191.84 Million ≈ $28.07 Million |
0.208x | +901.60% |
| 2017-12-31 | CN¥872.44 Million ≈ $127.67 Million |
CN¥18.10 Million ≈ $2.65 Million |
0.021x | +123.47% |
| 2016-12-31 | CN¥827.01 Million ≈ $121.02 Million |
CN¥7.68 Million ≈ $1.12 Million |
0.009x | -95.52% |
| 2015-12-31 | CN¥457.70 Million ≈ $66.98 Million |
CN¥94.88 Million ≈ $13.88 Million |
0.207x | -37.79% |
| 2014-12-31 | CN¥432.13 Million ≈ $63.23 Million |
CN¥144.00 Million ≈ $21.07 Million |
0.333x | +71.57% |
| 2013-12-31 | CN¥386.11 Million ≈ $56.50 Million |
CN¥74.99 Million ≈ $10.97 Million |
0.194x | -36.70% |
| 2012-12-31 | CN¥336.81 Million ≈ $49.29 Million |
CN¥103.34 Million ≈ $15.12 Million |
0.307x | +325.46% |
| 2011-12-31 | CN¥301.81 Million ≈ $44.16 Million |
CN¥-41.07 Million ≈ $-6.01 Million |
-0.136x | -- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more